Viela Bio

About Us


Partnering With Viela

Viela is dedicated to the development of novel, life-changing medicines for patients with a wide range of autoimmune and severe inflammatory diseases. We are currently partnered with Hansoh Pharmaceutical Group Company Limited (Hansoh Pharma) as well as Mitsubishi Tanabe Pharma, for the co-development and commercialization of inebilizumab-cdon in patients with NMOSD and other autoimmune diseases in China, Hong Kong and Macau, and Japan and other Asia regions, respectively.

We would welcome discussions on meaningful strategic collaborations with companies that share our mission to advance novel therapies for patients impacted by autoimmune disease. For additional information, please contact our business development team at